Tylosin Market to Surpass US$ 0.3 Billion Threshold by 2026 Globally

The global Tylosin market, by Drug Type (Tylosin Phosphate, Tylosin Tartrate, and Others), by Application (Felines, Canines, and Livestock), by Route of Administration (Oral and Injectable), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 379.0 million in 2017, and is projected to exhibit a CAGR of 1.2% over the forecast period (2018 – 2026). Availability of wide number of therapeutic options, and dosage strengths, antimicrobial efficacy and effectively, high prevalence of infectious diseases, and increasing demand for livestock is expected to fuel growth of the global Tylosin market. Tylosin is available under brand names such as Tylan (Tylosin Phosphate) by Elanco, Tylovet (Tylosin Phosphate) by Huvepharma, Tylan Soluble (Tylosin Tartrate) by Elanco, and others. The demand for antibiotics for against infection in livestock is on the rise, owing to increasing need for healthy livestock for human consumption. Antibiotics such as tylosin are used against mycoplasmosis in several animals such as chickens, turkeys, pigs, and calves. Tylosin is administered orally in required dosage in order to prevent said infections and to grow healthy livestock. Manufacturers such as Elanco Animal Health, Zoetis, Tairui Pharmaceuticals, AdvaCare Pharma, and another offer tylosin in various forms such as active pharmaceutical ingredient and solid dosage form and is generally available in veterinary soluble powder and granule forms.

The U.S. Food & Drug Administration (FDA) approved new combination uses of Zoetis feed additives ACTOGAIN 45 (ractopamine hydrochloride) and Engain (ractopamine hydrochloride) in 2015. ACTOGAIN 45 can be used with Rumensin (monensin USP) plus Tylovet 100 (tylosin phosphate). Browse 17 Market Data Tables and 20 Figures spread through 147 Pages and in-depth TOC on Tylosin Market, by Drug Type (Tylosin Phosphate, Tylosin Tartrate, and Others), by Application (Felines, Canines, and Livestock), by Route of Administration (Oral and Injectable), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2026

To know the latest trends and insights prevalent in the Tylosin Market, click the link below:

https://www.coherentmarketinsights.com/market-insight/tylosin-market-2061

Manufacturers are focused on adopting various strategies such as participation in events and meets, raising awareness about animal health, and marketing activities in order to showcase their products. For instance, Huvepharma participated in Respiratory Health Seminar for Pig Practitioners that took place in Belgium in 2017. Moreover, the company held its 5^th European seminar: Insights on Nutrition and Health of High Performing Animals in June 2018. Furthermore, in January 2018, Huvepharma acquired AgriLabs to expand the company’s presence in the U.S. Moreover, in 2015, Elanco released an eight-point antibiotic stewardship plan to outline global actions for the company to ensure long-term access to antibiotics for people and animals.

Key Takeaways of the Tylosin Market:

• The global tylosin market is expected to exhibit a CAGR of 2% over the forecast period (2018 – 2026), owing to various product offering by leading manufacturers
• North America and Europe is expected to retain dominant position in the Tylosin market over the forecast period due to presence of leading manufacturers and considerable usage of tylosin in the livestock industry
• Major players operating in the global tylosin market include, Zoetis, Inc., Tairui Pharmaceuticals, Lukang Pharmaceutical, Henan Hualun, Qilu Pharmaceutical (Inner Mongolia) Co., Ltd, Huvepharma, AdvaCare Pharma, and Elanco Animal Health.